Showing results (591-600 of 782) with videos related to

Sort By:
Pageof 79
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 4, 2015
A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma CellsAnnamaria Gullà, Maria Teresa Di Martino, Maria Eugenia Gallo Cantafio, et al.
Ebiomedicine|March 28, 2022
Indirubin-3'-monoxime acts as proteasome inhibitor: Therapeutic application in multiple myelomaZhen Yu, Xiaojing Wei, Lanting Liu, et al.
The Lancet. Oncology|September 24, 2013
Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind studyMeletios Dimopoulos, David S Siegel, Sagar Lonial, et al.
Blood Advances|December 5, 2020
Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data HubWilliam A Wood, Donna S Neuberg, J Colton Thompson, et al.
Molecular Cancer Therapeutics|May 20, 2016
Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple MyelomaNicola Amodio, Maria Angelica Stamato, Anna Maria Gullà, et al.
Blood Advances|October 21, 2021
ASH Research Collaborative: a real-world data infrastructure to support real-world evidence development and learning healthcare systems in hematologyWilliam A Wood, Peter Marks, Robert M Plovnick, et al.
Oncogene|August 11, 2005
FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignanciesJing Chen, Benjamin H Lee, Ifor R Williams, et al.
Blood|April 30, 2009
MicroRNAs 15a and 16 regulate tumor proliferation in multiple myelomaAldo M Roccaro, Antonio Sacco, Brian Thompson, et al.
Blood|December 17, 2008
microRNA expression in the biology, prognosis, and therapy of Waldenström macroglobulinemiaAldo M Roccaro, Antonio Sacco, Changzhong Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 24, 2006
Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myelomaLanie K Francis, Yazan Alsayed, Xavier Leleu, et al.
Pageof 79